A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of Multiple Ascending Doses of REL-1017 (d-Methadone) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Dextromethadone (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Acronyms MAD
- Sponsors Relmada Therapeutics
- 01 Apr 2019 Results from two studies evaluating the safety,pharmacokinetics and tolerability of oral doses of D-methadone in healthy opioid naive subjects,published in the Journal of Clinical Psychopharmacology
- 12 Dec 2018 According to a Relmada Therapeutics media release, the BDNF plasma level data from this study, were presented at the annual American College of Neuropsychopharmacology meeting.
- 12 Dec 2018 Results (BDNF plasma level data) presented in a Relmada Therapeutics media release.